[{"id":"129e5cf7-9e95-4c6e-b07f-53ac9b2b4f09","acronym":"","url":"https://clinicaltrials.gov/study/NCT04511871","created_at":"2025-02-26T06:48:17.814Z","updated_at":"2025-02-26T06:48:17.814Z","phase":"Phase 1","brief_title":"A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors","source_id_and_acronym":"NCT04511871","lead_sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CCT303-406"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/09/2020","start_date":" 07/09/2020","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 03/29/2025","study_completion_date":" 03/29/2025","last_update_posted":"2024-10-28"}]